Roberta Sarno, Digital Health Manager, Asia Pacific Medical Technology Association (APACMed), Singaporedigital health technologies.
What are the key scenarios that may act as hurdles against a proactive digital health adoption in the APAC region?
Healthcare systems across the Asia Pacific (APAC) region are highly fragmented, and the level of Digital Health (DH) adoption and maturity varies from country to country. As such, there is a wide variation in how DH solutions are brought to each market. However, some common challenges impeding the scale up of DH in APAC include the lack of regulatory guidelines, harmonised interoperability standards, cybersecurity and reimbursement frameworks.
One of the key factors that could accelerate DH adoption and deliver healthcare to people in a more accessible, affordable, and scalable way is having in place robust reimbursement frameworks specific for DH. To this end, the APACMed Digital Health Committee has developed a position paper identifying these hurdles and proposing customised frameworks that countries in the region could adopt, depending on their level of readiness and regulatory standards.
The committee identified three key barriers to digital health adoption in APAC:
Lack of value assessment frameworks specific to digital health
Fragmented and non-fit-for-purpose funding and reimbursement efforts
Complex evidence generation requirements and health financing schemes that are not appropriate for digital health technologies.
Unlike traditional medical devices and drugs, for which hard clinical outcomes are primarily used as a measure of success, DH has the potential to also look at efficiency gains and other factors to measure value such as, reducing physical touch points and visits to the physician, relative value units, health outcomes, enhanced efficiency in cost, time and resources.
This story is from the BioSpectrum Asia Sep 2021 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the BioSpectrum Asia Sep 2021 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Ushering Fourth Industrial Revolution in Telangana
Taking advantage of the 21st edition of BioAsia 2024 at the Hyderabad International Convention Centre (HICC) in Madhapur, the Government of Telangana, a southern state in India, leveraged the confluence of the global platform to spearhead initiatives aimed at propelling the state into the forefront of the Fourth Industrial Revolution (C4IR).
How Indian Biotech Investments are on a Doubling Spree
A latest report by Ankur Capital provides a closer look at the investments made in biotechnology in the last decade in the country.
"AI will be integrally involved in not only the diagnosis of cancer but also in determining the prognosis and best therapeutic option”
South Korea-based Deep Bio, a pioneering artificial intelligence (AI) healthcare firm focused on cancer pathology, is making waves in the industry.
"Because of its specificity and selectivity, ADCS have the potential to reduce adverse side effects and improve patient survival"
Japan-headquartered Daiichi Sankyo, the global healthcare company, launched its subsidiary Daiichi Sankyo Singapore Pte. Ltd. to bridge unmet needs in oncology.
Can Test, Treat, Track Beat Malaria?
Malaria has long been a major public health concern in the Asia Pacific region, particularly in South East Asia (SEA) affecting millions of people.
Engineering CAR T cell sharpshooters
Approved CAR T-cell therapies have shown remarkable results in patients with certain types of blood cancers.
Addressing Challenges in Cell Therapy Manufacturing
Even with significant advancements, there are still anumber of issues with cell therapy manufacturing that need to be resolved as production grows.
"We anticipate India will adopt decentralised models for managing CGTs, ensuring closer proximity between patients and treatment facilities"
Cell and gene therapy (CGT) expert from Germany, Miltenyi Biotec has recently announced its entry into the Indian market to provide researchers, scientists and clinicians easier access to expertise, research, and manufacturing solutions.
Addressing Accessibility and Affordability of CELL & GENE THERAPIES
Cell and gene therapies (CGT) are one of the hottest sectors in the pharmaceutical industry.
Korea designs sweat resistant wearable robot sensor
New electromyography (EMG) sensor technology that allows the long-term stable control of wearable robots and is not affected by the wearer's sweat and dead skin has gained attention recently.